SCHEMBL1912907

SCHEMBL1912907

BCc1cc(Cl)cc(C(F)(F)F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.39
TACR1 P25103 1/20 0.38
SLC6A4 P31645 1/20 0.38
KCNH2 Q12809 1/20 0.38
RAPGEF4 Q8WZA2 1/20 0.38
RHOC P08134 2/20 0.37
RHOA P61586 2/20 0.37
SLC13A3 Q8WWT9 1/20 0.36
AHR P35869 1/20 0.36
CYP3A4 P08684 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
MEN1 O00255 1/20 0.36
PLA2G1B P04054 1/20 0.36
CYP1A2 P05177 1/20 0.36
GAA P10253 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C19 P33261 1/20 0.36
KMT2A Q03164 1/20 0.36
ATG4B Q9Y4P1 1/20 0.36
P2RX1 P51575 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11984113 0.84 IDO1 (0.52) IDO1TACR1CYP3A4CYP2D6TSHR
SCHEMBL17062167 0.81 IDO1 (0.41) IDO1TACR1SLC6A4KCNH2RAPGEF4
SCHEMBL630541 0.79 RXRA (0.45) IDO1TACR1SLC6A4KCNH2RAPGEF4
SCHEMBL257077 0.79 RAPGEF4 (0.41) IDO1TACR1SLC6A4KCNH2RAPGEF4
SCHEMBL15516391 0.79 SLC13A3 (0.40) IDO1TACR1SLC6A4KCNH2RAPGEF4
SCHEMBL5730059 0.79 IDO1 (0.44) IDO1TACR1SLC6A4KCNH2RAPGEF4
SCHEMBL1229494 0.79 IDO1 (0.39) IDO1TACR1SLC6A4KCNH2RAPGEF4
SCHEMBL30302522 0.79 IDO1 (0.44) IDO1TACR1SLC6A4KCNH2RAPGEF4
SCHEMBL321756 0.77 AHR (0.52) IDO1RAPGEF4SLC13A3AHRCYP3A4
SCHEMBL3786224 0.77 RAPGEF4 (0.47) IDO1RAPGEF4RHOCRHOASLC13A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2404901-A1 1,2-Disubstituted 4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis Novartis AG (CH) 2012-01-11 EP disclosed
WO-2009071509-A1 1,2-DISUBSTITUTED-4-BENZYLAMINO-PYRROLIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLI PIDEMIA OR ARTERIOSCLEROSIS NOVARTIS AG (CH) 2009-06-11 WO disclosed